Leadership & Management
J&J MedTech appoints new ANZ leader
Leadership & Management: Johnson & Johnson has been appointed a new Managing Director for its medtech business in Australia and New Zealand, effective 28 October 2024. Sarah Najdek transitions into this role from her current position as Vice President of Cardiovascular Specialty Solutions Group, APAC, at Johnson & Johnson MedTech, which she has held over the past year.
Najdek succeeds Sue Martin, whose departure marks the end of a distinguished 23-year career at Johnson & Johnson, including seven years leading J&J MedTech across Australia and New Zealand.
“Sarah steps into this role after most recently leading the Electrophysiology, Neurovascular, and Mentor business unit in Asia Pacific. Sarah has consistently proven herself to be a customer-centric, tenacious leader with a strong bias for action and an exceptional ability to bring people together,” the company said in a statement.
A seasoned and commercially astute leader, Najdek brings over 20 years of strategic management experience across the manufacturing, medical device, and pharmaceutical industries in New Zealand, Australia, and Asia Pacific. In addition to her previous role as General Manager & Country Director for Johnson & Johnson MedTech New Zealand, she has served on the board of Johnson & Johnson MedTech ANZ and the Medical Technology Association of New Zealand (MTANZ).
Her career with Johnson & Johnson MedTech and Janssen has seen her hold senior leadership positions in diverse areas such as General Surgery, Bariatrics, Orthopaedics, Diabetes Management, Oncology, Immunology, and Medical Affairs. A passionate advocate for women in leadership, Najdek was also a founding member of J&J’s ANZ Diversity and Inclusion strategy committee.
In related news, Johnson & Johnson has announced that its medtech businesses – Ethicon, DePuy Synthes, Biosense Webster, Abiomed and CERENOVUS – will now operate under the unified name Johnson & Johnson MedTech. This is the next step of Johnson & Johnson’s updated brand and visual identity announced in September 2023.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
Leadership & Management
New Medicines Australia Chair critical to HTA reforms
Former MTPConnect Chair, Sue MacLeman, is taking the reins as Chair of Medicines Australia, bringing three decades of firepower in […]
MoreNews & Trends - Pharmaceuticals
PBS will never be subject to negotiation: Albanese rejects US pharma pressure at APP
Prime Minister Anthony Albanese has drawn a firm line in the sand, declaring that Australia’s Pharmaceutical Benefits Scheme (PBS) “will […]
MoreNews & Trends - MedTech & Diagnostics
Device implant to challenge weekly obesity injections in first Australian trial
Days following the announcement of the spin-off of its neurostimulation business to sharpen its focus on weight loss, obesity and […]
MoreNews & Trends - Pharmaceuticals
30% of IBD patients disconnected from clinicians: Professor Susie Connor
One in three Australians with inflammatory bowel disease (IBD) are leaving their medical appointments with critical misunderstandings about their condition […]
More